Biocontrol Technology
This article was originally published in The Gray Sheet
Executive Summary
BICO, Inc. subsidiary CEO and President David Purdy resigns following disagreement with parent company Chairman Fred Cooper over funding levels related to development of the Diasensor 2000 noninvasive blood glucose monitor, for which clinical trials are ongoing. Purdy, who resigned as BICO chairman in May to focus on the Diasensor, also faults a Sept. 8 BICO letter to stockholders for inaccuracies relating to the device. BICO maintains that "to date in year 2000, [it] has funded the Diasensor project in excess of $14 mil., which exceeds budget requirements by over $1 mil"
You may also be interested in...
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.
Swisse Supplements Take Bigger Slice Of Chinese Market
Australian-heritage Swisse grew its share of China's supplements market in 2023 by delivering tailored products to an increasingly health conscious population.